{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:17:47Z","timestamp":1765268267044,"version":"build-2065373602"},"reference-count":6,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2014,11,8]],"date-time":"2014-11-08T00:00:00Z","timestamp":1415404800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Development Research"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:table-wrap position=\"anchor\">\n\n<jats:table frame=\"hsides\">\n<jats:col\/>\n<jats:col\/>\n<jats:tbody>\n<jats:tr>\n<jats:td>Enabling Technology, Genomics, Proteomics<\/jats:td>\n<jats:td>Clinical Development Phases I\u2010III Regulatory, Quality, Manufacturing<\/jats:td>\n<\/jats:tr>\n<\/jats:tbody>\n<\/jats:table>\n\n<\/jats:table-wrap><\/jats:p><jats:p>Psoriasis (<jats:styled-content style=\"fixed-case\">Ps<\/jats:styled-content>) is a common and stigmatizing chronic inflammatory skin disease that may cause other chronic inflammatory conditions with overlapping pathology, such as rheumatoid arthritis (<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>). Tumor necrosis factor (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>) is a proinflammatory cytokine that plays a pivotal role in chronic inflammatory and autoimmune diseases such as uveitis, multiple sclerosis, systemic lupus, arthritis, <jats:styled-content style=\"fixed-case\">Ps<\/jats:styled-content>, and <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>rohn's disease. The <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> superfamily and receptors represent active targets for drug development. Anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> biological therapies, such as infliximab, adalimumab (<jats:styled-content style=\"fixed-case\">ADL<\/jats:styled-content>), and etanercept, are effective in treating <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>, spondyloarthritis, <jats:styled-content style=\"fixed-case\">Ps<\/jats:styled-content>, and inflammatory bowel diseases, but long\u2010term treatment can induce anti\u2010drug antibody (<jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content>) formation associated with lower drug levels and clinical nonresponse. An investigation of the relationship between serum <jats:styled-content style=\"fixed-case\">ADL<\/jats:styled-content>\/anti\u2010adalimumab antibody (<jats:styled-content style=\"fixed-case\">AAA<\/jats:styled-content>) concentration, and clinical response in moderate to severe <jats:styled-content style=\"fixed-case\">Ps<\/jats:styled-content>, confirmed an association between <jats:styled-content style=\"fixed-case\">ADL<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">AAA<\/jats:styled-content> levels and response. Although the detection of <jats:styled-content style=\"fixed-case\">ADAs<\/jats:styled-content> can be used to determine the cause of nonresponse and aid therapy decisions, the contrary observation of long\u2010term responders with low drug levels and detectable <jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content> suggests that another mechanism is also involved.<\/jats:p>","DOI":"10.1002\/ddr.21186","type":"journal-article","created":{"date-parts":[[2014,11,8]],"date-time":"2014-11-08T08:02:04Z","timestamp":1415433724000},"source":"Crossref","is-referenced-by-count":11,"title":["Detection of Adalimumab and Anti\u2010Adalimumab Levels by <scp>ELISA<\/scp>: Clinical Considerations"],"prefix":"10.1002","volume":"75","author":[{"given":"Barbara","family":"Marinari","sequence":"first","affiliation":[{"name":"Dermatology Unit NESMOS Department Sapienza University of Rome  Rome Italy"},{"name":"Skin Biology Laboratory Tor Vergata University of Rome  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Botti","sequence":"additional","affiliation":[{"name":"Dermatology Unit NESMOS Department Sapienza University of Rome  Rome Italy"},{"name":"Skin Biology Laboratory Tor Vergata University of Rome  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Bavetta","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tor Vergata University of Rome  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Spallone","sequence":"additional","affiliation":[{"name":"Skin Biology Laboratory Tor Vergata University of Rome  Rome Italy"},{"name":"Department of Dermatology Tor Vergata University of Rome  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Zangrilli","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tor Vergata University of Rome  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Talamonti","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tor Vergata University of Rome  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Richetta","sequence":"additional","affiliation":[{"name":"Dermatology Unit Medical Specialties Department Sapienza University of Rome  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Chimenti","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tor Vergata University of Rome  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Dermatology Unit NESMOS Department Sapienza University of Rome  Rome Italy"},{"name":"Skin Biology Laboratory Tor Vergata University of Rome  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-325225"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.406"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.065615"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.07.062"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04410.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21671"}],"container-title":["Drug Development Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fddr.21186","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddr.21186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:59:21Z","timestamp":1760345961000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/ddr.21186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":6,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1002\/ddr.21186"],"URL":"https:\/\/doi.org\/10.1002\/ddr.21186","archive":["Portico"],"relation":{},"ISSN":["0272-4391","1098-2299"],"issn-type":[{"type":"print","value":"0272-4391"},{"type":"electronic","value":"1098-2299"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}